CD33 and acute myeloid leukemia: In vivo experiments have shown that, in NGS mice, compared with the control group, which goes with the CAR T-cells targeting CD19 and CD7, AML cells (Molm14 and Kasumi) in the group with cells targeting only CD33 and the group with a combination of targeting CD33 and CD7 significantly decreased.